Wire · opportunities
OncoSil obtains FDA humanitarian exemption for bile duct cancer treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
OncoSil Medical received FDA humanitarian device exemption approval to treat distal cholangiocarcinoma, a rare and deadly bile duct cancer, with a beta radiation therapy platform. The US launch will begin at up to five treatment centers under a post-approval study, aiming for Q2 FY27.
This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 17 Aug 2026 and 18 Aug 2026.
◆ ◆ The Wire takeaway
You now have a rare path to US market access for treating bile duct cancer under FDA's humanitarian rules. Start building relationships with cancer centres and prepare for reimbursement talks before the device reaches those five pilot sites.
◆ Coverage
4 sources · first reported 17 Aug 2026 · latest 18 Aug 2026
◆ Related on Wire
◆ Topics